Genmab (GMAB) Stock Forecast, Price Target & Predictions
GMAB Stock Forecast
Genmab stock forecast is as follows: an average price target of $43.00 (represents a 109.76% upside from GMAB’s last price of $20.50) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
GMAB Price Target
The average price target for Genmab (GMAB) is $43.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $31.00. This represents a potential 109.76% upside from GMAB's last price of $20.50.
GMAB Analyst Ratings
According to 11 Wall Street analysts, Genmab's rating consensus is 'Buy'. The analyst rating breakdown for GMAB stock is 0 'Strong Buy' (0.00%), 8 'Buy' (72.73%), 3 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Genmab Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Vikram Purohit | Morgan Stanley | $31.00 | $27.41 | 13.10% | 51.22% |
| Aug 09, 2024 | Etzer Darout | BMO Capital | $46.00 | $27.07 | 69.93% | 124.39% |
| Jun 27, 2024 | Kaveri Pohlman | BTIG | $47.00 | $25.67 | 83.09% | 129.27% |
| Jun 27, 2024 | Raghuram Selvaraju | H.C. Wainwright | $50.00 | $25.71 | 94.48% | 143.90% |
| Jun 04, 2024 | Asthika Goonewardene | Truist Financial | $53.00 | $28.83 | 83.84% | 158.54% |
| Feb 23, 2024 | Etzer Darout | BMO Capital | $48.00 | $29.16 | 64.61% | 134.15% |
| Feb 06, 2023 | - | Leerink Partners | $36.00 | $38.26 | -5.91% | 75.61% |
| Nov 28, 2022 | Matthew Harrison | Morgan Stanley | $34.00 | $44.83 | -24.16% | 65.85% |
| May 02, 2022 | - | Cowen & Co. | $38.00 | $34.91 | 8.85% | 85.37% |
The latest Genmab stock forecast, released on Sep 04, 2024 by Vikram Purohit from Morgan Stanley, set a price target of $31.00, which represents a 13.10% increase from the stock price at the time of the forecast ($27.41), and a 51.22% increase from GMAB last price ($20.50).
Genmab Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $31.00 | $45.83 |
| Last Closing Price | $20.50 | $20.50 | $20.50 |
| Upside/Downside | -100.00% | 51.22% | 123.56% |
In the current month, the average price target of Genmab stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Genmab's last price of $20.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 11, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Sep 20, 2024 | Johnson Rice | Buy | Buy | Hold |
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 09, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Aug 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 01, 2024 | BTIG | Underperform | Underperform | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Genmab's last stock rating was published by H.C. Wainwright on Oct 16, 2024. The company gave GMAB a "Buy" rating, the same as its previous rate.
Genmab Financial Forecast
Genmab Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.85B | $5.23B | $4.09B | $3.16B | $2.12B | $2.62B | $2.31B | $1.97B | $1.58B | $2.04B | $1.72B | $5.45B | $892.00M | $2.96B | $1.04B |
| Avg Forecast | $7.88B | $7.59B | $7.39B | $6.29B | $6.68B | $6.30B | $6.10B | $4.76B | $6.15B | $5.53B | $5.08B | $3.97B | $4.55B | $4.55B | $4.10B | $2.77B | $4.71B | $3.61B | $2.93B | $2.02B | $2.55B | $2.17B | $1.70B | $1.39B | $1.77B | $1.51B | $5.72B | $890.63M | $2.67B | $933.08M |
| High Forecast | $8.28B | $7.98B | $7.76B | $6.61B | $7.02B | $6.63B | $6.41B | $4.98B | $6.52B | $5.55B | $5.08B | $3.97B | $4.78B | $5.03B | $4.31B | $2.91B | $4.95B | $3.61B | $2.93B | $2.02B | $2.55B | $2.17B | $1.70B | $1.39B | $1.77B | $1.51B | $5.72B | $890.63M | $2.67B | $933.08M |
| Low Forecast | $7.40B | $7.14B | $6.94B | $5.91B | $6.28B | $5.93B | $5.74B | $4.36B | $5.92B | $5.50B | $5.08B | $3.97B | $4.27B | $4.34B | $3.86B | $2.60B | $4.43B | $3.61B | $2.93B | $2.02B | $2.55B | $2.17B | $1.70B | $1.39B | $1.77B | $1.51B | $5.72B | $890.63M | $2.67B | $933.08M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 5 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.11% | 1.13% | 1.08% | 1.05% | 1.03% | 1.06% | 1.16% | 1.13% | 1.15% | 1.14% | 0.95% | 1.00% | 1.11% | 1.11% |
Genmab's average Quarter revenue forecast for Jun 23 based on 7 analysts is $4.10B, with a low forecast of $3.86B, and a high forecast of $4.31B. GMAB's average Quarter revenue forecast represents a 43.82% increase compared to the company's last Quarter revenue of $2.85B (Mar 23).
Genmab EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 5 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $629.00M | $2.81B | $2.03B | $2.69B | $550.00M | $969.00M | $1.40B | $852.00M | $1.43B | $-128.00M | $1.39B | $4.55B | $356.00M | $1.96B | $699.28M |
| Avg Forecast | $3.71B | $3.58B | $3.48B | $2.96B | $3.15B | $2.97B | $2.88B | $2.24B | $2.90B | $2.60B | $2.39B | $1.87B | $2.14B | $2.14B | $1.93B | $1.30B | $4.34B | $1.76B | $1.43B | $986.53M | $1.25B | $1.06B | $828.01M | $681.24M | $865.63M | $735.82M | $2.79B | $434.94M | $1.30B | $455.67M |
| High Forecast | $3.90B | $3.76B | $3.66B | $3.11B | $3.31B | $3.12B | $3.02B | $2.34B | $3.07B | $2.62B | $2.39B | $1.87B | $2.25B | $2.37B | $2.03B | $1.37B | $5.20B | $1.76B | $1.43B | $986.53M | $1.25B | $1.06B | $828.01M | $681.24M | $865.63M | $735.82M | $2.79B | $434.94M | $1.30B | $455.67M |
| Low Forecast | $3.49B | $3.36B | $3.27B | $2.79B | $2.96B | $2.79B | $2.70B | $2.05B | $2.79B | $2.59B | $2.39B | $1.87B | $2.01B | $2.04B | $1.82B | $1.23B | $3.47B | $1.76B | $1.43B | $986.53M | $1.25B | $1.06B | $828.01M | $681.24M | $865.63M | $735.82M | $2.79B | $434.94M | $1.30B | $455.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.48% | 0.65% | 1.15% | 1.88% | 0.56% | 0.78% | 1.32% | 1.03% | 2.09% | -0.15% | 1.89% | 1.63% | 0.82% | 1.51% | 1.53% |
7 analysts predict GMAB's average Quarter EBITDA for Jun 23 to be $1.93B, with a high of $2.03B and a low of $1.82B. This is 207.46% upper than Genmab's previous annual EBITDA (Mar 23) of $629.00M.
Genmab Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 5 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $226.00M | $584.00M | $2.58B | $1.89B | $465.00M | $716.00M | $890.00M | $306.00M | $1.10B | $581.00M | $530.00M | $3.38B | $269.00M | $1.47B | $537.05M |
| Avg Forecast | $3.38B | $3.01B | $2.76B | $1.89B | $1.84B | $1.62B | $1.50B | $700.07M | $1.59B | $1.34B | $1.40B | $6.61B | $1.38B | $1.51B | $1.28B | $5.93B | $3.20B | $1.08B | $895.75M | $5.29B | $635.73M | $546.69M | $294.16M | $5.73B | $483.58M | $392.72M | $3.50B | $1.78B | $1.44B | $242.06M |
| High Forecast | $3.60B | $3.21B | $2.94B | $2.01B | $1.97B | $1.72B | $1.60B | $746.55M | $2.23B | $1.34B | $1.40B | $7.93B | $2.11B | $1.88B | $1.37B | $7.11B | $3.85B | $1.08B | $895.75M | $6.34B | $635.73M | $546.69M | $294.16M | $6.87B | $483.58M | $392.72M | $3.50B | $2.14B | $1.44B | $242.06M |
| Low Forecast | $3.11B | $2.77B | $2.55B | $1.74B | $1.70B | $1.49B | $1.38B | $645.53M | $1.24B | $1.33B | $1.40B | $5.29B | $851.09M | $1.34B | $1.18B | $4.74B | $2.56B | $1.08B | $895.75M | $4.23B | $635.73M | $546.69M | $294.16M | $4.58B | $483.58M | $392.72M | $3.50B | $1.43B | $1.44B | $242.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.04% | 0.18% | 2.38% | 2.11% | 0.09% | 1.13% | 1.63% | 1.04% | 0.19% | 1.20% | 1.35% | 0.97% | 0.15% | 1.03% | 2.22% |
Genmab's average Quarter net income forecast for Jun 23 is $1.28B, with a range of $1.18B to $1.37B. GMAB's average Quarter net income forecast represents a 468.14% increase compared to the company's last Quarter net income of $226.00M (Mar 23).
Genmab SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 5 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $676.00M | $921.00M | $670.00M | $633.00M | $452.00M | $512.00M | $306.00M | $264.00M | $201.00M | $231.00M | $145.00M | $179.00M | $106.00M | $116.55M | $81.22M |
| Avg Forecast | $1.05B | $1.01B | $980.74M | $835.13M | $886.40M | $837.04M | $810.29M | $632.02M | $816.72M | $733.84M | $674.57M | $527.30M | $603.90M | $603.68M | $544.98M | $367.68M | $2.29B | $472.92M | $384.28M | $264.98M | $334.72M | $285.25M | $222.40M | $1.05B | $232.50M | $197.64M | $750.63M | $702.20M | $349.75M | $122.39M |
| High Forecast | $1.10B | $1.06B | $1.03B | $877.78M | $931.67M | $879.78M | $851.67M | $660.63M | $866.02M | $737.26M | $674.57M | $527.30M | $635.30M | $667.69M | $572.81M | $386.46M | $2.75B | $472.92M | $384.28M | $264.98M | $334.72M | $285.25M | $222.40M | $1.26B | $232.50M | $197.64M | $750.63M | $842.64M | $349.75M | $122.39M |
| Low Forecast | $983.16M | $947.62M | $921.95M | $785.08M | $833.27M | $786.87M | $761.72M | $579.01M | $786.28M | $730.42M | $674.57M | $527.30M | $566.75M | $575.98M | $512.32M | $345.64M | $1.83B | $472.92M | $384.28M | $264.98M | $334.72M | $285.25M | $222.40M | $839.95M | $232.50M | $197.64M | $750.63M | $561.76M | $349.75M | $122.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.84% | 0.40% | 1.42% | 1.65% | 1.71% | 1.53% | 1.07% | 1.19% | 0.19% | 0.99% | 0.73% | 0.24% | 0.15% | 0.33% | 0.66% |
Genmab's average Quarter SG&A projection for Jun 23 is $544.98M, based on 7 Wall Street analysts, with a range of $512.32M to $572.81M. The forecast indicates a -19.38% fall compared to GMAB last annual SG&A of $676.00M (Mar 23).
Genmab EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 7 | 3 | 2 | 2 | 5 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.35 | $0.89 | $3.96 | $2.89 | $0.71 | $1.09 | $1.36 | $0.47 | $1.68 | $0.89 | $0.81 | $5.19 | $0.41 | $2.30 | $0.84 |
| Avg Forecast | $5.21 | $4.64 | $4.26 | $2.91 | $2.84 | $2.49 | $2.31 | $1.08 | $2.45 | $2.06 | $2.16 | $1.29 | $2.12 | $2.33 | $1.98 | $0.64 | $2.34 | $1.67 | $1.38 | $0.53 | $0.98 | $0.84 | $0.45 | $0.29 | $0.75 | $0.61 | $5.39 | $0.13 | $2.21 | $0.37 |
| High Forecast | $5.55 | $4.95 | $4.54 | $3.10 | $3.03 | $2.66 | $2.46 | $1.15 | $3.44 | $2.07 | $2.16 | $1.34 | $3.25 | $2.90 | $2.11 | $0.68 | $2.49 | $1.67 | $1.38 | $0.53 | $0.98 | $0.84 | $0.45 | $0.29 | $0.75 | $0.61 | $5.39 | $0.13 | $2.21 | $0.37 |
| Low Forecast | $4.80 | $4.28 | $3.92 | $2.68 | $2.62 | $2.30 | $2.13 | $0.99 | $1.92 | $2.05 | $2.16 | $1.24 | $1.31 | $2.06 | $1.82 | $0.59 | $2.15 | $1.67 | $1.38 | $0.53 | $0.98 | $0.84 | $0.45 | $0.29 | $0.75 | $0.61 | $5.39 | $0.13 | $2.21 | $0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.38% | 2.37% | 2.09% | 1.33% | 1.11% | 1.62% | 1.03% | 5.76% | 1.20% | 1.34% | 0.96% | 3.27% | 1.04% | 2.25% |
According to 7 Wall Street analysts, Genmab's projected average Quarter EPS for Jun 23 is $1.98, with a low estimate of $1.82 and a high estimate of $2.11. This represents a 465.40% increase compared to GMAB previous annual EPS of $0.35 (Mar 23).
Genmab Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| APLS | Apellis Pharmaceuticals | $28.99 | $74.50 | 156.99% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| LEGN | Legend Biotech | $38.40 | $82.69 | 115.34% | Buy |
| GMAB | Genmab | $20.50 | $43.00 | 109.76% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| ASND | Ascendis Pharma | $124.44 | $190.21 | 52.85% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| PCVX | Vaxcyte | $87.08 | $124.00 | 42.40% | Buy |
| BGNE | BeiGene | $187.77 | $255.80 | 36.23% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.22 | $6.67 | 27.78% | Buy |
| TVTX | Travere Therapeutics | $17.39 | $21.75 | 25.07% | Buy |
| BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |
| ALEC | Alector | $3.85 | $4.00 | 3.90% | Buy |